Literature DB >> 6157503

Electrophoretic fractionation of serum gamma-glutamyl transpeptidase in human hepatic cancer.

J Kojima, M Kanatani, N Nakamura, T Kashiwagi, F Tohjoh, M Akiyama.   

Abstract

Serum gamma-glutamyl transpeptidase from patients with various hepatobiliary diseases was fractionated by polyacrylamide gradient gel slab electrophoresis to study the specific patterns of gamma-glutamyl transpeptidase fractions in hepatic cancer. On zymograms of normal serum gamma-glutamyl transpeptidase, a total of 10 fractions was observed. Additionally, fractions I', I" and II' were recognized in sera from hepatocellular carcinoma patients. Among these, fraction I', which migrated slightly, but significantly, slower than fraction I was the most specific; it was found in 55% of the hepatocellular carcinoma patients. Fractions I" and II' were also relatively specific, each was observed in about 29% of these patients. Fractions V to IX were observed in few hepatocellular carcinoma cases. Fraction I' is thought to be a hepatoma-related fraction, highly specific for the serum of hepatocellular carcinoma patients. Fractions I" and II' were also thought to be hepatoma-related fractions of gamma-glutamyl transpeptidase. We suggest that fractions I', I" and II' may be useful in the diagnosis of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6157503     DOI: 10.1016/0009-8981(80)90169-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein.

Authors:  R Cui; J He; F Zhang; B Wang; H Ding; H Shen; Y Li; X Chen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

Review 2.  Gamma-glutamyl transpeptidase: redox regulation and drug resistance.

Authors:  Marie H Hanigan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

Review 3.  Present and future possibilities for early diagnosis of hepatocellular carcinoma.

Authors:  Piotr Stefaniuk; Janusz Cianciara; Alicja Wiercinska-Drapalo
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

4.  Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma.

Authors:  Jing Zhu; Feng Jiang; Hong-Bing Ni; Ming-Bing Xiao; Bu-You Chen; Wen-Kai Ni; Cui-Hua Lu; Run-Zhou Ni
Journal:  Exp Ther Med       Date:  2012-10-31       Impact factor: 2.447

5.  Tumour-associated isoenzymes of gamma-glutamyl transferase in the serum of patients with hepatocellular carcinoma.

Authors:  M C Kew; P Wolf; D Whittaker; P Rowe
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.